Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01144494 · ClinicalTrials.gov registry record · Early Phase 1
Aqueous Humor Dynamics and Brimonidine
A Early Phase 1 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 35
- Enrollment target
NCT01144494: Completed Early Phase 1 study, sponsored by University of Nebraska.
NCT01144494 is a Early Phase 1 study that has completed, run by University of Nebraska. The registered enrollment target is 35 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01144494, a Early Phase 1 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This single-center, investigator-masked, crossover study is designed to investigate the circadian rhythms of aqueous humor dynamics in human subjects with ocular hypertension (OHT) before and after intervention with a commonly used ocular hypotensive medication, brimonidine for six weeks.
Primary Outcome
Seated day-time and supine day-time IOP was measured by pneumatonometer at 9 am and 11 am. Seated night-time IOP was measured at 9 pm and 11 pm.
Interventions
- DRUG Artificial tears
- DRUG Brimonidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2010-08-01 |
| Est. Completion | 2011-10-01 |
| Phase | Early Phase 1 |
What the finished NCT01144494 record still lists
NCT01144494 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 2 interventions - of which Artificial tears is the first listed.
NCT01144494 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01144494 about?
NCT01144494 is a clinical study titled "Aqueous Humor Dynamics and Brimonidine". This single-center, investigator-masked, crossover study is designed to investigate the circadian rhythms of aqueous humor dynamics in human subjects with ocular hypertension (OHT) before and after intervention with a commonly used ocular hypotensive medication, brimonidine for six weeks.
What is the current status of trial NCT01144494?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 35 participants. The study started on 2010-08-01. Estimated completion is 2011-10-01.
What interventions are being tested in trial NCT01144494?
The interventions under investigation include: Artificial tears (DRUG), Brimonidine (DRUG).
Who is sponsoring clinical trial NCT01144494?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01144494's enrollment target sits among peer trials
35 735th of 2000 higher than 1,254 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI